Adalimumab for the treatment of Crohn's disease

Expert Review of Clinical Immunology

Volumn 2, Issue 1, 2006, Pages 11-15

  Papadakis, Konstantinos A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PLACEBO; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BURNING SENSATION; CHRONIC DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GRANULOMATOUS INFLAMMATION; HEMORRHOID; HUMAN; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; NEPHROLITHIASIS; NONHUMAN; PERIANAL ABSCESS; PHARMACODYNAMICS; RECURRENT DISEASE; REMISSION; RHEUMATOID ARTHRITIS; SMALL INTESTINE; TUBERCULOSIS;

EID: 33748489767     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.1.11     Document Type: Article

References (28)

1. Papadakis KA, Tabibzadeh S. Diagnosis and misdiagnosis of inflammatory bowel disease. Gastrointest. Endosc. Clin. N. Am. 12(3), 433-449 (2002).
2. Andres PG, Friedman LS. Epidemiology and the natural course of Inflammatory Bowel Disease. Gastroenterol. Clin. N. Am. 28(2), 255-281 (1999).
3. Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur. J. Int. Med. 11, 191-196 (2000).
4. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157(3), 1261-1270 (1996).
5. Ina K, Itoh J, Fukushima K et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J. Immunol. 163(2), 1081-1090 (1999).
6. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann. Rev. Med. 51, 289-298 (2000).
7. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119(4), 1148-1157 (2000).
8. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337(15), 1029-1035 (1997).
9. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10(3), 387-398 (1999).
10. Plevy SE, Landers CJ, Prehn J et al. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. 159(12), 6276-6282 (1997).
11. Baert FJ, D'Haens GR, Peeters M et al. Tumor necrosis factor α antibody (infliximab) therapy profoundly down regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116(1), 22-28 (1999).
12. Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm. Bowel Dis. 10(Suppl. 2), S2-S10 (2004).
13. Podolsky DK. Inflammatory bowel disease. [see comment]. N. Engl. J. Med. 347(6), 417-429 (2002).
14. Hanauer SB. Inflammatory bowel disease. N. Engl. J. Med. 334(13), 841-848 (1996).
15. Sandborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev. Gastroenterol. Disord. 5(1), 10-18 (2005).
16. (Adalimumab) H: Abbott Laboratories (package insert). (2004).
17. Shen C, Assche GV, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21(3), 251-258 (2005).
18. Eissner G, Kirchner S, Lindner H et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J. Immunol. 164(12), 6193-6198 (2000).
19. Paulson SK, Noertersheuser P, Pollack PF, Hoffman RS. Pharmacokinetics of adalimumab from CLASSIC, a randomized Phase 3 trial for the induction of clinical remission in patients with Crohn's disease. Gastroenterology 128, A585 (2005) (Abstract).
20. Lee SJ, Kavanaugh A. Adalimumab for the treatment of rheumatoid arthritis. Therapy 2, 13-21 (2005).
21. Hanauer S, Lukas M, Macintosh D et al. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology 127, 332 (2004) (Abstract).
22. Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterology 99(10), 1984-1989 (2004).
23. Youdim A, Vasiliauskas EA, Targan SR et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm. Bowel Dis. 10(4), 333-338 (2004).
24. Papadakis KA, Shaye OA, Vasiliauskas EA et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. [see comment]. Am. J. Gastroenterology 100(1), 75-79 (2005).
25. Sandborn WJ, Hanauer S, Lukas M et al. Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF-α monoclonal antibody adalimumab (Humira). Gastroenterology 128(Suppl. 2), 723, A111 (2005) (Abstract).
26. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann. Pharmacother. 37(9), 1256-1265 (2003).
27. Keystone EC. Safety of biologic therapies - an update. J. Rheumatol. 74(Suppl.), 8-12 (2005).
28. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin. Gastroenterol. Hepatol. 2, 309-313 (2004).